What Mass Balance does

Mass Balance Limited is a privately held UK-incorporated space biotechnology company, founded in 2025, with headquarters in London and a research and development operation in Bengaluru, India. The company operates with 1–10 employees and is positioned at the intersection of structural biology and orbital research, targeting pharmaceutical and biotechnology customers that require access to protein structures that cannot be reliably analyzed under terrestrial gravity.

The company's sole product is SpaceFold™, a proprietary, trademarked platform that leverages microgravity conditions in orbit to enable structural analysis of proteins that are otherwise difficult or impossible to study on Earth. The stated value proposition is drug discovery against "undruggable" protein targets, with Cancer Research UK partnership suggesting an applied focus in oncology. Mission 1 is scheduled for Q2 2026, and the company is actively collecting expressions of interest for Mission 2, implying a mission-based service or collaboration delivery model.

Commercially, Mass Balance is pre-revenue. No pricing is publicly disclosed, no contracts are evidenced, and no funding rounds are captured in the source data. Operational access to microgravity is secured through core strategic partnerships with the UK Space Agency, ESA, and Catapult, supplemented by supporting relationships with Cancer Research UK, CPI, and BIA. The go-to-market posture is partnership- and collaboration-driven rather than product-sales-driven at this stage, with the website functioning as the primary customer-acquisition surface for prospective mission participants.

Name

Mass Balance

Legal name

Mass Balance Limited

Website

https://massbalance.bio

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Mass Balance is a UK-based space biotechnology company using its proprietary SpaceFold™ microgravity platform to analyze protein structures and enable drug discovery against previously undruggable targets for pharmaceutical and biotechnology customers.

Ownership category

akta.pro rank

Product category

Space Biotechnology / Microgravity Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Guided Missiles & Space Vehicles & Parts (3760)

akta.pro primary industry

Space Payloads & Instruments (Sensors, Comms, EO/IR) (IMABACAD)

Keywords

• Microgravity drug discovery
• Protein structure analysis
• Space biotechnology
• Undruggable protein targets
• Orbital research platform

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Marketing channels1 record

Core offering

Mass Balance operates a proprietary microgravity-based research platform called SpaceFold™ that enables structural analysis of proteins difficult or impossible to study under Earth's gravity, targeting drug discovery for previously undruggable protein targets. The company delivers its research capabilities through orbital missions — Mission 1 is scheduled to launch in Q2 2026, and Mission 2 is currently accepting participant seats — for pharmaceutical and biotechnology partners.

Product overview

Mass Balance operates as a space biotechnology company offering a single unified platform product called SpaceFold™. This technology leverages microgravity conditions in orbit to enable researchers to analyze and drug challenging protein structures that cannot be studied using conventional Earth-based methods. The company is structured around space missions (Mission 1 launching Q2 2026, Mission 2 accepting seats) that deliver their research capabilities to customers.

Differentiator

Problem solved

Functional benefit

Brands

• SPACEFOLD™: Proprietary technology platform using microgravity to study and develop protein-based therapeutics, enabling the study of protein structures that are difficult to analyze under normal gravity conditions.

Products and services

• SpaceFold™ Proprietary microgravity-based technology platform that uses orbital conditions to enable structural analysis and drug discovery for unruly proteins that are otherwise difficult or impossible to study under Earth's gravity, targeting the undruggable proteome for pharmaceutical and biotechnology partners.
• Orbital Research Missions (Mission 1 and Mission 2) Orbital research missions delivered via the SpaceFold™ platform, providing pharmaceutical and biotechnology customers with access to microgravity-based protein structural analysis and drug discovery research; missions are sold as discrete research service engagements with reserved participant seats.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core and supporting.

• UK Space AgencycoreStrategic or Co-development PartnerInstitutional partner supporting Mass Balance's orbital research operations. The UK Space Agency logo appears prominently on the company's website alongside other mission partners, indicating active support for the company's microgravity research initiatives.
• ESA (European Space Agency)coreStrategic or Co-development PartnerEuropean Space Agency collaboration providing access to orbital infrastructure and microgravity research capabilities essential to SpaceFold™ technology operations.
• CatapultsupportingStrategic or Co-development PartnerCatapult (likely Satellite Applications or similar UK Catapult) provides innovation support and potentially orbital research facilitation for Mass Balance's microgravity experiments.
• Cancer Research UKsupportingStrategic or Co-development PartnerLeading cancer research charity partner, likely providing research collaboration and drug discovery expertise in oncology applications for the SpaceFold™ platform.
• CPI (Centre for Process Innovation)supportingStrategic or Co-development PartnerCPI provides innovation and bioprocessing expertise, supporting Mass Balance's development of novel drug discovery methodologies using microgravity conditions.
• BIA (BioIndustry Association)supportingStrategic or Co-development PartnerUK BioIndustry Association membership and collaboration provides industry networking, advocacy, and potential partnership introductions for the biotech sector.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Schrödinger: Public computational chemistry and biology platform used widely by pharma for structure-based drug design. Comparable structural-biology-driven drug discovery angle, but offers broadly adopted terrestrial software rather than an orbital research service.
• Recursion Pharmaceuticals: Public AI-driven drug discovery platform using high-throughput biology and computational methods to pursue novel targets. Comparable 'taming intractable biology' positioning, though operates at much larger scale and on terrestrial infrastructure.
• Voyager Space: Commercial space station developer (Starlab, with Airbus) building infrastructure expected to host biotech and pharma microgravity research. Comparable orbital-biology customer segment, but operates as a station infrastructure provider rather than a focused drug discovery platform.
• Axiom Space: Commercial space infrastructure provider building private space stations with planned biotech and pharmaceutical research capacity. Comparable orbital biotech customer base, but supplies station hardware and access rather than a specific protein-folding service like SpaceFold™.

Emerging players

• Varda Space Industries: US company building in-space manufacturing and biotech payload platforms, including microgravity-enabled pharmaceutical crystallization and formulation. Comparable orbital biotech payload model, though focused on small-molecule crystallization rather than protein folding.
• BioOrbit: UK-based space pharma startup developing microgravity-based drug formulation and biologics manufacturing in orbit. Comparable geography, customer segment (pharma), and orbital bioprocessing thesis to Mass Balance.
• Isomorphic Labs: Alphabet-backed drug discovery company built on AlphaFold pursuing computational approaches to the 'undruggable' proteome. Comparable end-customer segment (pharma targeting novel protein classes) and adjacent technology approach to Mass Balance's microgravity thesis.

Others

• Redwire Space: Commercial space company providing biotech payload hardware and ISS experiment services, including microgravity research facilities. Adjacent enabler for orbital biotech research with similar customers, but supplies hardware and integration services rather than running drug discovery itself.

Direct peers

• Space Tango: US-based microgravity research services company operating payload facilities on the ISS for biotech, pharma, and academic customers. Closely comparable mission-based service model and customer profile to Mass Balance's SpaceFold™.
• SpacePharma: Israel-based microgravity biotech company offering end-to-end orbital lab services for pharmaceutical and biological research. Directly comparable to Mass Balance as a space-based contract research platform targeting drug discovery and life sciences customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mass Balance